<DOC>
	<DOCNO>NCT01485081</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Danubio Paclitaxel Eluting Balloon treatment side branch de novo bifurcation lesion native coronary artery .</brief_summary>
	<brief_title>Safety Efficacy Study DANUBIO Paclitaxel Eluting Balloon Side Branches de Novo Bifurcation Lesions ( DEBSIDE )</brief_title>
	<detailed_description>The DEBSIDE clinical trial prospective , non-randomized , multicenter , interventional study evaluate investigational Danubio Paclitaxel Eluting Coronary Balloon treatment Side Branches ( SB ) de novo bifurcation lesion side branch reference vessel diameter ≥2.0 mm ≤3.0 mm . During procedure , dedicate drug-eluting bifurcate stent implant main branch . The trial allow treatment lesion Medina type except ( 0,0,1 ) native coronary artery sequential predilatation main side branch . The DEBSIDE clinical trial enroll 60 patient . All patient receive Quantitative Coronary Angiography ( QCA ) Drug-Eluting Balloon ( DEB ) inflation 6 month follow-up . All patient clinical follow-up 1 , 6 12 month .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . De novo bifurcation lesion follow Medina classification except ( 0,0,1 ) . 2 . Reference diameter main branch &gt; = 2.5 ≤ 3.5 mm side branch &gt; = 2.0 ≤ 3.0 mm . 3 . Main branch lesion length ≤ 26mm side branch lesion ≤ 6mm . For 24mm stent main branch : main branch lesion length ≤ 14mm proximal ≤ 12mm distal carina . For 18mm stent main branch : main branch lesion length ≤ 8mm proximal ≤ 12mm distal carina . Indeed additional stent ( Amazonia PAX 8mm ) overlap distally Nile PAX target lesion segment ≤4mm remain uncovered implantation bifurcate stent . 4 . Maximum two bifurcation lesion per patient two different vessel least one lesion treat procedure describe protocol ( involve Danubio ) . 5 . The side branch bifurcation involve target lesion must treat trial device ( Danubio ) . 6 . During index procedure , case : Treatment lesion vessel target vessel , Treatment lesion target vessel distal target bifurcation lesion , The treatment nontarget lesion must successfully perform DrugEluting Stent treatment target lesion ( residual stenosis &lt; 30 % ; stent well deploy ; residual dissection ; normal TIMI flow ; chest pain ; ECG unchanged compare preprocedural ECG ) . 7 . Successful sequential main branch side branch predilatation conventional balloon provide good angiographic result ( i.e . absence dissection , TIMI &gt; III ) . 8 . The patient least 18 year age . 9 . Non menopausal woman must provide negative pregnancy test use double contraception end study . 10 . The patient clinical evidence ischemic heart disease , stable unstable angina sign ischemia , silent ischemia , positive functional test . 11 . The patient acceptable candidate percutaneous transluminal coronary angioplasty ( PTCA ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery . 12 . The patient patient 's legal representative inform nature trial agrees provision provide write informed consent approve Ethics Committee ( EC ) . 13 . The patient agree return research facility require angiographic postprocedure followup visit 6 month 1 . De novo bifurcation lesion Medina ( 0,0,1 ) . 2 . Left main bifurcation . 3 . The Danubio cover beyond side branch lesion distally &lt; 2mm . 4 . The stent cover beyond main branch lesion proximally distally &lt; 2mm . 5 . Heavily calcified lesion . 6 . Severe tortuous lesion . 7 . Evidence extensive thrombosis dissection within target vessel intervention 8 . Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % recent evaluation . 9 . Main branch target lesion stented device Nile PAX . 10 . Dissection require additional treatment main side branch target lesion main branch stent implantation . 11 . Untreated significant lesion &gt; 50 % diameter stenosis remain proximal distal target lesion 12 . A known hypersensitivity contraindication aspirin , heparin bivaluridin , ticlopidine clopidogrel , paclitaxel drug similar class , cobalt chromium alloy , contrast medium , adequately premedicated . 13 . Chronic total occlusion ( CTO ) . 14 . A serum creatinine level &gt; 2.0mg/dL within seven day prior index procedure . 15 . Evidence acute MI within 72 hour intend index procedure ( accord ARC definition ) . 16 . Previous Percutaneous Coronary Interventions ( PCI ) target lesion . 17 . Previous PCI target vessel within 9 month preprocedure . 18 . Planned PCI vessel within 30 day postprocedure . 19 . Surgery 30 day prior PCI anticipate surgery 6months post PCI . 20 . During index procedure , target lesion require treatment device PTCA prior use Danubio ( include limit cut balloon , atherectomy , laser , thrombectomy , etc. ) . 21 . Second lesion require treatment target vessel . 22 . Second bifurcation lesion require treatment . 23 . History stroke transient ischemic attack ( TIA ) within prior 6 month . 24 . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month . 25 . History bleed diathesis coagulopathy refuse blood transfusion . 26 . Concurrent medical condition life expectancy le 12 month . 27 . Any previous plan treatment target vessel antirestenotic therapy include , limited brachytherapy . 28 . Currently participate investigational drug another device trial complete primary endpoint clinically interfere current trial endpoint , require coronary angiography , IVUS coronary artery imaging procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Bifurcation</keyword>
	<keyword>Drug-eluting balloon</keyword>
	<keyword>Paclitaxel-eluting balloon</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Coronary artery stenosis</keyword>
</DOC>